Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...
The FDA has approved Argenx SE's (NASDAQ:ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult ...
Credit: Argenx. Vyvgart Hytrulo is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase. The Food and Drug Administration (FDA) has approved ...
PANGYO, South Korea--(BUSINESS WIRE)--Huonslab, Co. Ltd. S. Korea, a subsidiary of Huons Global (KOSDAQ:084110) and a global leader in recombinant human hyaluronidase-based biologics Sub-Q delivery, ...
Opinions expressed by Digital Journal contributors are their own. Gaining worldwide recognition is a huge accomplishment that only a few medical experts reach. It’s not just about having excellent ...
Huonslab Co., Ltd., a subsidiary of Huons Global (KOSDAQ:084110), announced that it has obtained a patent for the formulation without serum albumin of HYDIZYME™ (Recombinant Human Hyaluronidase PH20, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback